Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (November 2024)

29 slides from Centessa Pharmaceuticals's investor presentation, Nov 12, 2024

  1. Slide 1: November 2024 Corporate Overview

    Slide 1: November 2024 Corporate Overview

    November 2024 Corporate Overview

  2. Slide 2: Disclaimer and Forward Looking Statements

    Slide 2: Disclaimer and Forward Looking Statements

    2 DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential

  3. Slide 3: Discovering and Developing Medicines that are Transformational for Patients

    Slide 3: Discovering and Developing Medicines that are Transformational for Patients

    Discovering and Developing Medicines that are Transformational for Patients 3 Potential best-in-class / first-in-class orexin agonist franchise Ongoing momentum in 2024 with clinical milestones anticipated across our orexin agonist pipeline in 2025 Strong balance sheet OUR MISSION Centessa reported

  4. Slide 4: Our Most Advanced Potential Best-in-Class / First-in-Class Medicines for Patients

    Slide 4: Our Most Advanced Potential Best-in-Class / First-in-Class Medicines for Patients

    4 Our Most Advanced Potential Best-in-Class / First-in-Class Medicines for Patients Centessa has multiple early-stage assets not reflected on this slide. ASSET DISEASE/CONDITION MECHANISM PRE-CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL ORX750 Narcolepsy Type 1 (NT1) OXR2 Agonist ORX750 Narcolepsy Type 2

  5. Slide 5: 2024 Driving Momentum: Anticipated Milestones

    Slide 5: 2024 Driving Momentum: Anticipated Milestones

    5 2024 Driving Momentum ANTICIPATED MILESTONES LOCKBODY TECHNOLOGY PLATFORM LB101 Phase 1/2a study ongoing OREXIN AGONIST PROGRAM ORX750 Initiated Phase 2a study in patients with NT1, NT2, and IH; Data expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 IND-enabling studies ongo

  6. Slide 6: Orexin Agonist Program

    Slide 6: Orexin Agonist Program

    6 LockBody Technology Platform Orexin Agonist Program

  7. Slide 7: Orexin agonists have the potential to transform the standard of care

    Slide 7: Orexin agonists have the potential to transform the standard of care

    Orexin agonists have the potential to transform the standard of care for individuals with sleep-wake, neurological, neurodegenerative and psychiatric disorders 7

  8. Slide 8: Centessa is Developing a Pipeline of Orexin Receptor 2 Agonists

    Slide 8: Centessa is Developing a Pipeline of Orexin Receptor 2 Agonists

    8 Centessa is Developing a Pipeline of Potential Best-in-Class / First-in-Class Orexin Receptor 2 (OX2R) Agonists ORX750 for the treatment of NT1, NT2 and IH ORX142 for the treatment of neurological, neurodegenerative and psychiatric disorders Earlier stage OX2R agonists and therapeutics for additio

  9. Slide 9: ORX750 a Potential Best-in-Class Oral OX2R Agonist for NT1, NT2 and IH

    Slide 9: ORX750 a Potential Best-in-Class Oral OX2R Agonist for NT1, NT2 and IH

    9 ORX750 a Potential Best-in-Class Oral OX2R Agonist for the Treatment of NT1, NT2 and IH Favorable safety and tolerability profile;1 No observations of hepatotoxicity, visual disturbances or hallucinations, as of Oct. 31, 2024 data cutoff date1 MWT (Maintenance of Wakefulness Test); Phase 1 study o

  10. Slide 10: ORX750 First-in-Human Healthy Volunteer Study

    Slide 10: ORX750 First-in-Human Healthy Volunteer Study

    10 PHASE 1 STUDY ORX750 First-in-Human Healthy Volunteer (HV) Study Phase 1 clinical study of ORX750: Evaluate the safety, tolerability and pharmacokinetics (PK) of single-ascending and multiple-ascending doses in healthy adult subjects In parallel Efficacy assessments are being performed using the

  11. Slide 11: SAD Combined with Efficacy Assessment in Acutely Sleep-Deprived HV

    Slide 11: SAD Combined with Efficacy Assessment in Acutely Sleep-Deprived HV

    SAD Combined with Efficacy Assessment in Acutely Sleep-Deprived HV ORX750 Placebo Placebo ORX750 Washout MWT and KSSMWT and KSS N=12 HVs per cohort, randomized to ORX750 (N=9) or placebo (N=3) Dose escalate based on review of data from each cohort N≥10 HVs per cohort from SAD 1:1 randomization ORX75

  12. Slide 12: ORX750 Demonstrated Dose-Dependent Improvements in Mean Sleep Latency

    Slide 12: ORX750 Demonstrated Dose-Dependent Improvements in Mean Sleep Latency

    ORX750 Demonstrated Dose-Dependent and Significant Improvements in Mean Sleep Latency INTERIM PHASE 1 ORX750 LS Mean (95% CI) Sleep Latency (Minutes) Placebo LS Mean (95% CI) Sleep Latency (Minutes) LS Mean Difference Compared to Placebo (95% CI) p-Value 1.0 mg (n=8) 18 (12, 23) 10 (4, 15) 8 (0, 16)

  13. Slide 13: ORX750 Demonstrated a Favorable Safety and Tolerability Profile

    Slide 13: ORX750 Demonstrated a Favorable Safety and Tolerability Profile

    13 ORX750 Demonstrated a Favorable Safety and Tolerability Profile in Both Single and Multiple Dose Studies INTERIM PHASE 1 SAD Cohorts MAD Cohorts Placebo (n=15) ORX750 1.0 mg (n=9) ORX750 2.0 mg (n=9) ORX750 2.5 mg (n=9) ORX750 3.5 mg (n=9) ORX750 5.0 mg (n=9) Placebo (n=4) ORX750 2.0 mg (n=8) ORX

  14. Slide 14: Phase 2a Study of ORX750 in Patients with NT1, NT2, IH

    Slide 14: Phase 2a Study of ORX750 in Patients with NT1, NT2, IH

    14 PHASE 2a STUDY Phase 2a Study of ORX750 in Patients with NT1, NT2, IH Evaluate safety, tolerability, and pharmaco- kinetics in NT1, NT2, and IH patients Efficacy assessments will evaluate excessive daytime sleepiness using the Maintenance of Wakefulness Test (MWT)* and Epworth Sleepiness Scale (E

  15. Slide 15: Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750

    Slide 15: Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750

    After each 2-week period, treatment assignment (ORX750 or Placebo) may change PHASE 2a STUDY Randomized, Double-blind, Placebo-Controlled Basket Study of ORX750 in Patients with NT1, NT2, and IH Innovative design with potential to enable well-powered and efficient data generation All patients to rec

  16. Slide 16: ORX142 Demonstrated High In Vitro Potency and Selectivity

    Slide 16: ORX142 Demonstrated High In Vitro Potency and Selectivity

    ORX142 Demonstrated High In Vitro Potency and Selectivity Activation pattern was comparable to OXA with lack of biased agonism1 No significant differences in OX2R potency were observed across species2 No significant pharmacological activity observed in GPCR selectivity and in vitro safety panels3 16

  17. Slide 17: ORX142 Increased Wakefulness in Non-Human Primates

    Slide 17: ORX142 Increased Wakefulness in Non-Human Primates

    ORX142 (mg/kg, p.o.) ORX142 Increased Wakefulness and Decreased NREM and REM Sleep in Non-Human Primates (NHPs) ORX142 preclinical data presentation at the European Sleep Research Congress, September 26, 2024. 4 males and 3 females used; EEG, EMG recorded using intraperitonially implanted telemeters

  18. Slide 18: ORX489 Designed as a Highly Potent and Selective OX2R Agonist

    Slide 18: ORX489 Designed as a Highly Potent and Selective OX2R Agonist

    -12 -10 -8 -6 0 25 50 75 100 Log concentration (M) Activation (% total) ORX489 Designed as a Highly Potent and Selective OX2R Agonist Activation pattern was indistinguishable from OXA with lack of biased agonism1 No significant differences in OX2R potency were observed across species2 No significant

  19. Slide 19: Building a Multi-Asset Orexin Agonist Franchise

    Slide 19: Building a Multi-Asset Orexin Agonist Franchise

    ORX750 Sleep-Wake Disorders NT1, NT2 & IH $5B+ potential market opportunity ORX142 & ORX489 Neurological, Neurodegenerative and Psychiatric Disorders $10B+ potential market opportunity 19 Building a Multi-Asset Orexin Agonist Franchise Source: Evaluate Pharma 2030 projected sales for narcolepsy – sa

  20. Slide 20: Orexin Agonist Program Milestones

    Slide 20: Orexin Agonist Program Milestones

    20 OREXIN AGONIST PROGRAM ORX750 Initiated Phase 2a study in patients with NT1, NT2, and IH; Data expected in 2025 Presentation of Phase 1 data planned for Q2 2025 ORX142 IND-enabling studies ongoing; Clinical data in acutely sleep- deprived healthy volunteers expected in 2025 ORX489 Entering IND-en

  21. Slide 21: LockBody Technology Platform

    Slide 21: LockBody Technology Platform

    21 LockBody Technology Platform Orexin Agonist Program

  22. Slide 22: LockBody Technology Platform aims to redefine immuno-oncology treatment

    Slide 22: LockBody Technology Platform aims to redefine immuno-oncology treatment

    22 LockBody Technology Platform aims to redefine immuno-oncology treatment Novel pharmacology combining tumor enrichment with activation of effector function Designed as single agent systemic treatment Potential wide therapeutic index1 LB101 is an investigational agent that has not been approved by

  23. Slide 23: Locked Configuration MOA

    Slide 23: Locked Configuration MOA

    Locked Configuration MOA LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 23

  24. Slide 24: Unlocked Configuration MOA

    Slide 24: Unlocked Configuration MOA

    Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody MOA 24

  25. Slide 25: Significant Tumor Regression Observed In-Vivo with LB101

    Slide 25: Significant Tumor Regression Observed In-Vivo with LB101

    Significant Tumor Regression Observed In-Vivo with LB101 Source: In vivo- 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Data presented at ASCO in June 2022. https://investors.centessa.com/static-files/2f9bffb4-97a6-4320-8885- 70f12aa4d036. MC38 hPD-L1+ syngeneic model in mouse. Triang

  26. Slide 26: LB101 Well Tolerated in Non-Human Primates

    Slide 26: LB101 Well Tolerated in Non-Human Primates

    Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50mg/kg Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates. No anemia/ thrombocytopenia No weight loss No change in red blood cell or hemoglobin 26 PRECLINICAL DATA

  27. Slide 27: LB101 is in an ongoing Phase 1/2a first-in-human clinical trial

    Slide 27: LB101 is in an ongoing Phase 1/2a first-in-human clinical trial

    LB101 is in an ongoing Phase 1/2a first-in-human clinical trial 27

  28. Slide 28: Discovering and Developing Medicines that are Transformational for Patients

    Slide 28: Discovering and Developing Medicines that are Transformational for Patients

    Discovering and Developing Medicines that are Transformational for Patients 28 Potential best-in-class / first-in-class orexin agonist franchise Ongoing momentum in 2024 with clinical milestones anticipated across our orexin agonist pipeline in 2025 Strong balance sheet OUR MISSION Centessa reported

  29. Slide 29: - n —) < 1S) ke =) lu (3) < = a < a5

    Slide 29: - n —) < 1S) ke =) lu (3) < = a < a5

    - n —) < 1S) ke =) lu (3) < = a < a5 (,

Source: SEC EDGAR · 8-K filed Nov 12, 2024

More decks from Centessa Pharmaceuticals PLC